29 November 2021: Clinical Research
Combined Use of Transjugular Intrahepatic Portosystemic Shunt and Transarterial Chemoembolization in the Treatment of Esophageal and Gastric Variceal Bleeding: A Retrospective Study of 80 Patients with Hepatocellular Carcinoma and Portal Hypertension
Xinhua Zou AB , Miao Xue BCDE , Jiaping Li EFG*DOI: 10.12659/MSM.934436
Med Sci Monit 2021; 27:e934436
Table 1 Baseline demographic and clinical characteristics of patients enrolled in this study.
| Characteristic | TIPS+TACE (n=42) | Endoscopy+TACE (n=38) | χ2 | t | P | |
|---|---|---|---|---|---|---|
| Sex (n/%) | Male | 29 (69.05%) | 26 (68.42%) | 0.004 | – | 0.952 |
| Female | 13 (30.95%) | 12 (31.58%) | ||||
| Age (median±SD) | Years | 47.24±7.86 | 46.08±7.32 | – | 0.684 | 0.496 |
| Child-Pugh classification (n/%) | A | 9 (21.43%) | 9 (23.68%) | 0.067 | – | 0.967 |
| B | 22 (52.38%) | 19 (50.00%) | ||||
| C | 11 (26.19) | 10 (26.32%) | ||||
| Viral hepatitis | HBV | 38 (90.48%) | 34 (89.48%) | 0.557 | – | 0.757 |
| HCV | 1 (2.38%) | 2 (5.26%) | ||||
| None | 3 (7.14%) | 2 (5.26%) | ||||
| HCC size | >5 cm | 23 (54.76%) | 19 (50.00%) | 0.290 | – | 0.865 |
| 3–5 cm | 13 (30.95%) | 12 (31.58%) | ||||
| 6 (14.29%) | 7 (18.42%) | |||||
| Number of tumors | >5 | 7 (16.67%) | 6 (15.79%) | 0.297 | – | 0.862 |
| 3–5 | 14 (33.33%) | 15 (39.47%) | ||||
| 21 (50.00%) | 17 (44.74%) | |||||
| MVI | With | 8 (19.05%) | 6 (15.79%) | 0.942 | – | 0.332 |
| Without | 34 (80.95%) | 32 (84.21%) | ||||
| EHS | Lung | 2 (4.76%) | 2 (5.26%) | 0.750 | – | 0.687 |
| Lymph nodes | 3 (7.15%) | 2 (5.26%) | ||||
| Bone | 2 (4.76%) | 0 (0.00%) | ||||
| TACE times | – | 2.87±0.32 | 2.75±0.41 | – | 1.359 | 0.183 |
| TIPS – transjugular intrahepatic portosystemic shunt; TACE – transarterial chemoembolization; HBV – viral hepatitis B; HCV – viral hepatitis C; HCC – hepatocellular carcinoma; EHS – extrahepatic spread; MVI – macroscopic vascular invasion. | ||||||